Online inquiry

IVTScrip™ mRNA-Anti-MSLN, BAY 94-9343(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3727MR)

This product GTTS-WQ3727MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets MSLN gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001177355.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10232
UniProt ID Q13421
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MSLN, BAY 94-9343(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ3727MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7046MR IVTScrip™ mRNA-Anti-VEGFA, Fab-12 variant Y0317(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA Fab-12 variant Y0317
GTTS-WQ5642MR IVTScrip™ mRNA-Anti-TNF, CDP870(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CDP870
GTTS-WQ8290MR IVTScrip™ mRNA-Anti-GHR, HM10560A(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA HM10560A
GTTS-WQ12712MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, OMP-305B83(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA OMP-305B83
GTTS-WQ8244MR IVTScrip™ mRNA-Anti-PDCD1, HLX10(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HLX10
GTTS-WQ2693MR IVTScrip™ mRNA-Anti-SOST, AMG 785 (Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG 785
GTTS-WQ1090MR IVTScrip™ mRNA-Anti-SLAMF7, ABBV-838(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ABBV-838
GTTS-WQ8187MR IVTScrip™ mRNA-Anti-FCGRT, HL161(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA HL161
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW